Posted on 11/8/18
Seres Therapeutics Reports Third Quarter Financial Results and Provides Operational Updates
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (NASDAQ:MCRB) today reported third quarter 2018 financial results and provided an operational update.“Based on a growing body of promising clinical data . . .
Posted on 11/8/18
Eloxx Pharmaceuticals Reports Third Quarter 2018 Financial and Operating Results and Provides Business Update
WALTHAM, Mass., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc., (NASDAQ: ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics . . .
Posted on 11/8/18
Here's Why Alnylam Pharmaceuticals Crashed 11.9% on Wednesday
What happenedShares of Alnylam Pharmaceuticals (NASDAQ:ALNY) finished down 11.9% on Wednesday, following the biotech's third-quarter earnings release.This is the first earnings report following the approval of . . .
Posted on 11/8/18
Charles River Laboratories International Inc (CRL) Q3 2018 Earnings Conference Call Transcript
IMAGE SOURCE: THE MOTLEY FOOL.Charles River Laboratories International Inc (NYSE:CRL)Q3 2018 Earnings Conference CallNov. 07, 2018, 8:30 a.m. ETContents: Prepared RemarksQuestions and AnswersCall ParticipantsPrepared Remarks:OperatorLadies and . . .
Posted on 11/7/18
Verastem Oncology Announces Collaboration with The Leukemia & Lymphoma Society
BOSTON, Mass.--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq: VSTM), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced a . . .
Posted on 11/7/18
Alnylam Pharmaceuticals Reports Third Quarter 2018 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter 2018 and reviewed recent commercial . . .
Posted on 11/7/18
Charles River Laboratories Announces Third-Quarter 2018 Results
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the third quarter of 2018. For the quarter, revenue was $585.3 million, . . .
Posted on 11/7/18
Merrimack Reports Third Quarter 2018 Financial Results and Provides Strategic Update Following Portfolio Review
Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK), a research and clinical development oncology company focused on biomarker-defined cancers, today announced its third quarter 2018 financial results for the . . .
Posted on 11/7/18
Momenta Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update
CAMBRIDGE, Mass., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) today reported its financial results for the third quarter ended September 30, 2018 . . .
Posted on 11/7/18
Melinta Therapeutics Reports Third Quarter 2018 Financial Results
NEW HAVEN, Conn., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company, developing and commercializing novel antibiotics to treat serious bacterial . . .
Posted on 11/6/18
Momenta Pharmaceuticals Announces Global Settlement with AbbVie
CAMBRIDGE, Mass., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) today announced that it has executed agreements with AbbVie Inc., providing license rights . . .
Posted on 11/6/18
Vericel Reports Record Q3 Revenues of $22.5 Million
CAMBRIDGE, Mass., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, . . .
Posted on 11/6/18
Health First Selects Kyruus Solutions to Enable Digital Patient Access Initiatives
BOSTON--(BUSINESS WIRE)--Kyruus, a leader in provider search and scheduling solutions for health systems, today announced that Health First, a not-for-profit integrated delivery network in Florida, has . . .
Posted on 11/6/18
CVS Health Reports Third Quarter Results
Third Quarter Year-over-Year Highlights: Net revenues increased 2.4% to $47.3 billionSame store prescription volume growth of 9.2%Pharmacy Services claims growth of 5.7%GAAP diluted EPS from continuing . . .
Posted on 11/6/18
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, . . .
Posted on 11/6/18
EyePoint Pharmaceuticals and Ocumension Therapeutics Sign Exclusive License Agreement
WATERTOWN, Mass., Nov. 05, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, and Ocumension . . .
Posted on 11/5/18
Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on November . . .
Posted on 11/5/18
Bristol-Myers Squibb and Infinity Pharmaceuticals Announce a New Clinical Collaboration
NEW YORK & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced a clinical trial collaboration to evaluate Bristol-Myers Squibb's . . .
Posted on 11/5/18
Flex Pharma Reports Third Quarter 2018 Financial Results
BOSTON--(BUSINESS WIRE)--Flex Pharma, Inc. (NASDAQ: FLKS), today announced its financial results for the three months ended September 30, 2018.On June 13, 2018, the Company announced that . . .
Posted on 11/5/18
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor . . .
Posted on 11/2/18
Intensity Therapeutics Raises $6.5 Million in Series B
Intensity Therapeutics, Inc., a clinical-stage biotechnology company developing proprietary immune cell-activating cancer treatments
Posted on 11/2/18
Innovation Pharmaceuticals Expands Brilacidin Patent Portfolio
BEVERLY, Mass., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals, (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to report that the U.S. Patent . . .
Posted on 11/2/18
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Oct. 31, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a leader in precision genetic medicine for rare diseases, granted equity awards on October . . .
Posted on 11/2/18
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
BOSTON, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon . . .
Posted on 11/1/18
Akoya Biosciences Acquires Phenoptics Portfolio from PerkinElmer
Akoya Biosciences, a Telegraph Hill Partners (THP) company, has acquired PerkinElmer, Inc.’s Phenoptics portfolio.

